Madrid

• Modified autologous leukocyte cells for the treatment of acute kidney injury after cardiac surgery Ended recruitment
  2023-504610-30-01 4 2026-04-29 Acute kidney injury after cardiac surgery
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• An open-label study to investigate ECUR-506 in male children less than 9 months of age with neonatal onset OTC deficiency Ended recruitment
  2023-506180-34-01 7 2026-04-10 Ornithine Transcarbamylase Deficiency (OTC)
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended recruitment
  2025-521918-26-00 4 2026-02-11 HIV Infections
• Phase I Study of Plitidepsin Administered Intravenously as a Single Dose in Healthy Volunteers Ended recruitment
  2024-513664-25-00 3 2026-01-26 Virus diseases
• Safety, tolerance and antiretroviral activity of IMP: a pilot clinical trial in patients with recent HIV-1 infection Ended recruitment
  2024-519641-30-00 4 2026-01-26 Asymptomatic patients with recent HIV-1 infection
• A Study Evaluating BFB759 in Atopic Dermatitis Ended recruitment
  2025-521624-30-00 4 2026-01-08 Atopic dermatitis
• Pharmacokinetic Study of Rezafungin in Patients with Suspected Intra-Abdominal Candidiasis: Peritoneal Diffusion and Candicidal Activity Ended recruitment
  2025-521854-40-00 6 2025-12-22 Intra-Abdominal Candidiasis.
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038) Ended recruitment
  2025-521970-33-00 5 2025-12-19 ​​Pulmonary Arterial Hypertension (PAH)
• A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou … Ended recruitment
  2025-522598-12-00 10 2025-12-17 Untreated Metastatic Pancreatic Ductal Adenocarcinoma
• A Phase 1/2a Study of UCART22 in B-cell Acute Lymphoblastic Leukemia (BALLI-01) Ended recruitment
  2022-502305-15-00 7 2025-11-26 Relapsed or refractory B-cell Acute Lymphoblastic Leukemia
• Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part … Ended recruitment
  2023-506146-23-00 4 2025-11-17 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
• MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended recruitment
  2023-503539-16-00 5 2025-11-11 Non-small Cell Lung Cancer (NSCLC)
• DOSE-FINDING CLINICAL TRIAL TO EVALUATE OF INTESTINAL LACTASE ACTIVITY VIA ORAL GAXILOSE ADMINISTRATION IN HEALTHY ADULT VOLUNTEERS Ended recruitment
  2025-521308-23-00 3 2025-11-07 Hypolactasia
• A study of S095035 as a single agent and in combination in adult participants with advanced or metastatic solid tumors with deletion of MTAP Ended recruitment
  2025-521249-25-00 7 2025-10-30 MTAP-deleted advanced or metastatic solid tumors
• A study to test the safety, dosage and effectiveness of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adole … Ended recruitment
  2023-508988-73-00 5 2025-10-29 Cytomegalovirus (CMV) infection in children and adolescents who have r
• Master protocol of novel agents or combinations as perioperative treatment in participants with locally advanced resectable gastroesophagea … Ended recruitment
  2024-516909-23-00 4 2025-10-28 Locally Advanced Resectable Gastroesophageal Adenocarcinoma
• A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended recruitment
  2024-519469-23-00 4 2025-10-20 Severe Asthma
• A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended recruitment
  2024-519743-15-00 5 2025-10-20 Influenza immunisation
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended recruitment
  2025-521681-10-00 4 2025-10-02 Lung Cancer
• An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachmen … Ended recruitment
  2025-520629-19-00 3 2025-10-01 HIV Infections
• A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended recruitment
  2024-518811-20-00 4 2025-09-30 Early-Stage, PIK3CA-Mutated Breast Cancer (BC)
• Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Ended recruitment
  2025-521115-40-00 4 2025-09-30 Advanced or Metastatic Non-small Cell Lung Cancer

Showing 1,657–1,680 of 3,550 trials